ROUKEN
LIVE

Serial Number

79422824

Owner

Antibody Analytics Limited

Attorney

Alexandra MacKay

Filing Date

Nov 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ROUKEN Trademark

Serial Number: 79422824

ROUKEN is a trademark filed by Antibody Analytics Limited on November 26, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Antibody Analytics Limited

Antibody Analytics Discovery Centre,

Entity Type: 99

Trademark Details

Filing Date

November 26, 2024

Registration Date

Not Registered

Published for Opposition

January 20, 2026

Goods & Services

Scientific and medical research and development services for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical research laboratory services; research and development services in the field of antibodies and antibody technology; advisory services relating to the development of chemical reagents; scientific and industrial research services in the fields of biotechnology, pharmaceuticals, immunology, cell engineering, immunoassays and pharmacogenetics; laboratory services namely, research, analysis, characterising and development of therapeutic proteins and human antibodies; development and design of scientific analytical testing methodologies; medical and scientific research into new drug candidates; industrial analysis and research services, in particular for selecting, characterising and preparing immunoglobulins, antibodies or parts thereof; research and development services in the field of immunology; DNA sequencing services being identification of immunogenic sequences and peptides; sequence discovery services in the nature of DNA sequencing technology research; medical and scientific immunotoxicology research and analysis services; medical immunogenicity research and analysis services; pharmaceutical drug development services; development of gene-based medicines; research and development of vaccines and medicines; biological cloning services; biological research and analysis; biological drug development services; laboratory research services relating to pharmaceuticals; providing laboratory research services in the field of biopharmaceuticals; chemical, biochemical, biological and bacteriological research and analysis; medical and scientific research and development services in the field of molecular science; medical and scientific analysis services in the field of molecular biology and molecular genetics; diagnostic services in the field of immunology; providing reagent sample testing and diagnostic services for others for scientific research purposes; scientific consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; providing information about medical research in the fields of biopharmaceuticals, immunology, cell engineering and immunoassays; consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; custom design and development of chemical reagents and biochemical assays; scientific research in the field of genetics and genetic engineering; genetic sequencing analysis services for scientific and medical research purposes; medical and scientific research services analysing the safety and efficacy of new pharmaceuticals; research in the field of cell engineering technology; cell engineering services, namely cell suppression and cell activation; medical and scientific research, development, engineering and testing services in the fields of bioanalytical assays, assay development and antigen binding; medical and scientific research, development, engineering and testing services in the fields of immunotherapies, antibody-based molecules and targeted protein degraders; medical and scientific research, development, engineering and testing services in the fields of molecular biology, biophysics, DNA replication and replication of immune cell interaction in the tumour microenvironment; medical and scientific research, development, engineering and testing services in the field of biopharmaceutical modulating therapeutics; compiling and analysing data for research purposes in the field of medical science and medical consultancy; authentication of data in the field of immunology; cell culture services for scientific and research purposes, for others; DNA sequencing technology research; medical and scientific research, development, engineering and testing services in the fields of immunopharmaceuticals, vaccines and oncology; consultancy, information and advisory services relating to all of the aforesaid services

Chemicals used in industry and science; chemicals and reagents for scientific or medical research purposes; chemical preparations, substances and reagents for analysis in laboratories, not for medical or veterinary purposes; diagnostic preparations, not for medical or veterinary purposes; reagents used for research purposes, in particular, for medical research; reagents used for chemical analyses, not for medical or veterinary purposes; scientific reagents, not for medical or veterinary purposes; chemicals for scientific and research use in the field of immunology; reagents used for scientific and research purposes in the field of immunoserology; diagnostic and testing reagents for scientific use, not for medical or veterinary purposes; immunoassay reagents, other than for medical use; laboratory chemicals and reagents for scientific use and medical research; biochemical reagents used for non-medical purposes; biochemicals being monoclonal antibodies used for non-medical purposes; immunogens, immunoglobulins, antibodies, peptides and proteins for scientific and medical research services; biological activators, namely, preparations for clinical or medical laboratory use; biological preparations for use as assay samples for research analysis purposes in the field of medical research; reagents for use in scientific apparatus for chemical or biological analysis; biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays used for non-medical purposes; diagnostic preparations for scientific or research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs used for non-medical purposes; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for non-medical purposes; reagents for scientific and research use; assays and reagents for use in genetic research; cell culture reagents for scientific and research use; protein for industrial use; protein in raw material form for scientific and medical research; assays for research purposes; biochemicals, namely, polypeptides for in vitro research use; biochemicals, namely, DNA, RNA and oligonucleotides for in vitro research use; cells for scientific and research use; immune cells for scientific and research use; T cells for scientific and research use; primary cells for scientific and research use; immortalised cells for scientific and research use; biological tissue, namely, blood, stem cells, disease state tissue, healthy donor tissue, healthy donor blood, human biopsy tissue, umbilical cords and placentas for scientific and medical research use

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for medical purposes, namely, biological preparations for the diagnoses and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; large molecules for medical purposes being chemical reagents for medical purposes; biological tissue cultures for medical purposes; biological tissue cultures for medical use; diagnostic preparations for medical purposes, namely, biological tissue; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; mixed biological preparations for the prevention and treatment of infectious diseases; biological and chemical preparations and reagents for medical or veterinary use; antiserums for diagnostic purposes for diagnoses of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; diagnostic reagents for medical use; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; in vitro diagnostic preparations for medical use; diagnostic preparations for medical or veterinary purposes; diagnostic reagents and contrast media for medical use; diagnostic agents, preparations and substances for medical purposes; medical diagnostic reagents and assays for testing body fluids for microorganisms; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; antibodies for medical purposes; in-vivo diagnostic agent used for detection and monitoring of angiogenesis and anti-angiogenic therapy; diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; reagents for medical use; chemical reagents for medical purposes; reagents for use in medical genetic testing; enzymes for medical purposes; cells for medical or clinical use; culture media for cultivating human cells and microorganism cells for medical purposes; immunoassay reagents for medical use; assay platforms for medical use for detecting and analysing proteins, nucleic acids, small molecules, cells, pathogens and lipids; immunology assays for medical use for detecting and analysing proteins, nucleic acids, small molecules, cells, pathogens and lipids; antigens for medical use; antiviral T cells for medical use; human immune cells, in particular T cells, for medical or clinical purposes; human primary cells for medical and clinical use; immortalised human cells for medical and clinical use; target antigens for medical use; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, and for the treatment of inflammatory disorders for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; vaccine preparations; therapeutic vaccines

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 20, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jan 20, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Jan 15, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 14, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 31, 2025 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 30, 2025 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 18, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 17, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 17, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 17, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 16, 2025 GNFN
FINAL REFUSAL E-MAILED
Dec 16, 2025 GNFR
FINAL REFUSAL WRITTEN
Dec 16, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2025 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Nov 29, 2025 NREP
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 5, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 5, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 5, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 5, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 5, 2025 COAR
REFUSAL PROCESSED BY IB
Aug 2, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 16, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 15, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 23, 2025 RFCR
NON-FINAL ACTION WRITTEN
May 22, 2025 CNRT
ASSIGNED TO EXAMINER
May 19, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
May 2, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 2, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 1, 2025 REPR